Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer

被引：1

作者：

Zhang, Xuebao ^{[1
]}

Liu, Chu ^{[1
]}

Li, Kui ^{[2
]}

Wang, Ke ^{[3
]}

Zhang, Qiqiang ^{[1
]}

Cui, Yuanshan ^{[1
]}

机构：

[1] Qingdao Univ, Dept Urol, Affiliated Yantai Yuhuangding Hosp, 20 East Yuhuangding Rd, Yantai 264000, Shandong, Peoples R China

[2] Peoples Hosp Yucheng, Dept Urol Surg, Yucheng, Peoples R China

[3] Qingdao Univ, Dept Urol, Affiliated Hosp, Qingdao, Shandong, Peoples R China

来源：

MEDICINE | 2019年 / 98卷 / 06期

关键词：

clinical efficacy; custirsen; meta-analysis; prostate cancer; RANDOMIZED PHASE-II; CLUSTERIN EXPRESSION; OPEN-LABEL; ANTISENSE OLIGONUCLEOTIDE; INCREASED SURVIVAL; PLUS PREDNISONE; IN-VITRO; DOCETAXEL; OGX-011; CELL;

D O I：

10.1097/MD.0000000000014254

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Custirsen is the second-generation antisense oligonucleotide (ASO), which can reduce cellular levels of clusterin to increase the cytotoxic effect of chemotherapeutic drugs. Our study assessed the efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer (mCRPC).We conducted a comprehensive search to identify all the randomized controlled trials (RCTs) of custirsen for the treatment of mCRPC. The reference lists of the retrieved studies were investigated.Three publications involving a total of 1709 patients were used in the analysis. We found that overall survival (OS) (P=.25) was not statistically significant in the comparison. Safety assessments indicated custirsen were often associated with complications resulting from neutropenia (P<.001), anaemia (P<.001), thrombocytopenia (P<.001), and diarrhea (P=.002).Our meta-analysis shows that custirsen has no obvious effect on improving the OS of patients with mCRPC. Adverse reactions were more common among those patients treated with custirsen as compared to those treated with placebo.

引用

页数：6

共 41 条

[1] Custirsen (OGX-011): Clusterin Inhibitor in Metastatic Prostate Cancer [J].

Al-Asaaed, Sohaib ;

Winquist, Eric .

CURRENT ONCOLOGY REPORTS, 2013, 15 (02) :113-118

[2]

Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095

[3] Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial [J].

Beer, Tomasz M. ;

Hotte, Sebastien J. ;

Saad, Fred ;

Alekseev, Boris ;

Matveev, Vsevolod ;

Flechon, Aude ;

Gravis, Gwenaelle ;

Joly, Florence ;

Chi, Kim N. ;

Malik, Zafar ;

Blumenstein, Brent ;

Stewart, Patricia S. ;

Jacobs, Cindy A. ;

Fizazi, Karim .

LANCET ONCOLOGY, 2017, 18 (11) :1532-1542

[4] Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial [J].

Chi, Kim N. ;

Higano, Celestia S. ;

Blumenstein, Brent ;

Ferrero, Jean-Marc ;

Reeves, James ;

Feyerabend, Susan ;

Gravis, Gwenaelle ;

Merseburger, Axel S. ;

Stenzl, Arnulf ;

Bergman, Andries M. ;

Mukherjee, Som D. ;

Zalewski, Pawel ;

Saad, Fred ;

Jacobs, Cindy ;

Gleave, Martin ;

de Bono, Johann S. .

LANCET ONCOLOGY, 2017, 18 (04) :473-485

[5] Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer [J].

Chi, Kim N. ;

Hotte, Sebastien J. ;

Yu, Evan Y. ;

Tu, Dongsheng ;

Eigl, Bernhard J. ;

Tannock, Ian ;

Saad, Fred ;

North, Scott ;

Powers, Jean ;

Gleave, Martin E. ;

Eisenhauer, Elizabeth A. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) :4247-4254

[6] A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer [J].

Chi, KN ;

Eisenhauer, E ;

Fazli, L ;

Jones, EC ;

Goldenberg, SL ;

Powers, J ;

Tu, DS ;

Gleave, ME .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17) :1287-1296

[7] Potential roles of antisense technology in cancer chemotherapy [J].

Crooke, ST .

ONCOGENE, 2000, 19 (56) :6651-6659

[8] Abiraterone and Increased Survival in Metastatic Prostate Cancer [J].

De Bono, Johann S. ;

Logothetis, Christopher J. ;

Molina, Arturo ;

Fizazi, Karim ;

North, Scott ;

Chu, Luis ;

Chi, Kim N. ;

Jones, Robert J. ;

Goodman, Oscar B., Jr. ;

Saad, Fred ;

Staffurth, John N. ;

Mainwaring, Paul ;

Harland, Stephen ;

Flaig, Thomas W. ;

Hutson, Thomas E. ;

Cheng, Tina ;

Patterson, Helen ;

Hainsworth, John D. ;

Ryan, Charles J. ;

Sternberg, Cora N. ;

Ellard, Susan L. ;

Flechon, Aude ;

Saleh, Mansoor ;

Scholz, Mark ;

Efstathiou, Eleni ;

Zivi, Andrea ;

Bianchini, Diletta ;

Loriot, Yohann ;

Chieffo, Nicole ;

Thian Kheoh ;

Haqq, Christopher M. ;

Scher, Howard I. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) :1995-2005

[9] Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial [J].

de Bono, Johann Sebastian ;

Oudard, Stephane ;

Ozguroglu, Mustafa ;

Hansen, Steinbjorn ;

Machiels, Jean-Pascal ;

Kocak, Ivo ;

Gravis, Gwenaelle ;

Bodrogi, Istvan ;

Mackenzie, Mary J. ;

Shen, Liji ;

Roessner, Martin ;

Gupta, Sunil ;

Sartor, A. Oliver .

LANCET, 2010, 376 (9747) :1147-1154

[10] METAANALYSIS IN CLINICAL-TRIALS [J].

DERSIMONIAN, R ;

LAIRD, N .

CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188

← 1 2 3 4 5 →